(ERA) Eramet - Ratings and Ratios
Manganese, Nickel, Alloys, Mineral Sands, Lithium
| Risk via 10d forecast | |
|---|---|
| Volatility | 43.7% |
| Value at Risk 5%th | 65.0% |
| Relative Tail Risk | -9.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.31 |
| Alpha | 1.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.555 |
| Beta | 0.185 |
| Beta Downside | 0.424 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.54% |
| Mean DD | 35.79% |
| Median DD | 38.86% |
Description: ERA Eramet November 12, 2025
Eramet S.A. (ticker ERA) is a French-based diversified metals miner that extracts and processes manganese, nickel, mineral sands and lithium. Its asset base spans the Moanda manganese mine in Gabon, nickel operations in New Caledonia and Indonesia, and a mineral-sand project in Senegal, supplying a broad product slate that includes silicomanganese alloys, ferronickel, nickel pig iron, and titanium-bearing sands used in ceramics and abrasives.
Key financial and market drivers (as of FY 2023) include an EBITDA of €1.2 bn, a net-debt-to-EBITDA ratio of roughly 2.5×, and exposure to commodity cycles-particularly manganese prices, which have risen >30 % year-over-year on tightening supply, and nickel, which is sensitive to EV battery demand and the rollout of the EU’s Green Deal. A material ESG risk is the reliance on the Moanda mine, where community and regulatory pressures have historically impacted production continuity.
For a deeper, data-rich assessment of Eramet’s valuation dynamics and scenario analysis, you may find the research tools on ValueRay worth exploring.
ERA Stock Overview
| Market Cap in USD | 1,808m |
| Sub-Industry | Diversified Metals & Mining |
| IPO / Inception | |
| Return 12m vs S&P 500 | -8.54% |
| Analyst Rating | - |
ERA Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 2.46% |
| Yield on Cost 5y | 4.52% |
| Yield CAGR 5y | -22.54% |
| Payout Consistency | 60.3% |
| Payout Ratio | 300.0% |
ERA Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -10.92% |
| CAGR/Max DD Calmar Ratio | -0.17 |
| CAGR/Mean DD Pain Ratio | -0.31 |
| Current Volume | 39.5k |
| Average Volume | 39.5k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-127.0m TTM) > 0 and > 6% of Revenue (6% = 357.6m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -23.17pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.53% (prev 17.17%; Δ -4.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 114.0m > Net Income -127.0m (YES >=105%, WARN >=100%) |
| Net Debt (1.88b) to EBITDA (441.0m) ratio: 4.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (28.6m) change vs 12m ago -0.69% (target <= -2.0% for YES) |
| Gross Margin 45.22% (prev 17.85%; Δ 27.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 95.33% (prev 104.1%; Δ -8.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.39 (EBITDA TTM 441.0m / Interest Expense TTM 217.0m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 15.74
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -42.27% = -5.0 |
| 3. FCF Margin -23.27% = -7.50 |
| 4. Debt/Equity 2.37 = 0.21 |
| 5. Debt/Ebitda 4.25 = -2.50 |
| 6. ROIC - WACC (= -8.12)% = -10.15 |
| 7. RoE -8.95% = -1.49 |
| 8. Rev. Trend -60.59% = -4.54 |
| 9. EPS Trend -35.65% = -1.78 |
What is the price of ERA shares?
Over the past week, the price has changed by +4.07%, over one month by -8.19%, over three months by +5.88% and over the past year by +4.77%.
Is ERA a buy, sell or hold?
What are the forecasts/targets for the ERA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 50.3 | -8.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 55.4 | 0.8% |
ERA Fundamental Data Overview November 18, 2025
Market Cap EUR = 1.56b (1.56b EUR * 1.0 EUR.EUR)
P/E Forward = 10.1626
P/S = 0.5344
P/B = 1.492
Beta = 0.922
Revenue TTM = 5.96b EUR
EBIT TTM = -84.0m EUR
EBITDA TTM = 441.0m EUR
Long Term Debt = 2.02b EUR (from longTermDebt, last quarter)
Short Term Debt = 406.0m EUR (from shortTermDebt, last quarter)
Debt = 2.47b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.88b EUR (from netDebt column, last quarter)
Enterprise Value = 3.28b EUR (1.56b + Debt 2.47b - CCE 746.0m)
Interest Coverage Ratio = -0.39 (Ebit TTM -84.0m / Interest Expense TTM 217.0m)
FCF Yield = -42.27% (FCF TTM -1.39b / Enterprise Value 3.28b)
FCF Margin = -23.27% (FCF TTM -1.39b / Revenue TTM 5.96b)
Net Margin = -2.13% (Net Income TTM -127.0m / Revenue TTM 5.96b)
Gross Margin = 45.22% ((Revenue TTM 5.96b - Cost of Revenue TTM 3.27b) / Revenue TTM)
Gross Margin QoQ = 65.07% (prev 52.50%)
Tobins Q-Ratio = 0.53 (Enterprise Value 3.28b / Total Assets 6.15b)
Interest Expense / Debt = 3.00% (Interest Expense 74.0m / Debt 2.47b)
Taxrate = -33.58% (negative due to tax credits) (45.0m / -134.0m)
NOPAT = -112.2m (EBIT -84.0m * (1 - -33.58%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.54 (Total Current Assets 2.14b / Total Current Liabilities 1.39b)
Debt / Equity = 2.37 (Debt 2.47b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = 4.25 (Net Debt 1.88b / EBITDA 441.0m)
Debt / FCF = -1.35 (negative FCF - burning cash) (Net Debt 1.88b / FCF TTM -1.39b)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.07% (Net Income -127.0m / Total Assets 6.15b)
RoE = -8.95% (Net Income TTM -127.0m / Total Stockholder Equity 1.42b)
RoCE = -2.44% (EBIT -84.0m / Capital Employed (Equity 1.42b + L.T.Debt 2.02b))
RoIC = -3.07% (negative operating profit) (NOPAT -112.2m / Invested Capital 3.65b)
WACC = 5.05% (E(1.56b)/V(4.03b) * Re(6.70%) + D(2.47b)/V(4.03b) * Rd(3.00%) * (1-Tc(-0.34)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -2.38%
Fair Price DCF = unknown (Cash Flow -1.39b)
EPS Correlation: -35.65 | EPS CAGR: -24.69% | SUE: 0.0 | # QB: 0
Revenue Correlation: -60.59 | Revenue CAGR: -14.28% | SUE: -0.07 | # QB: 0